HC Wainwright Reaffirms “Buy” Rating for Atossa Therapeutics (NASDAQ:ATOS)

HC Wainwright reiterated their buy rating on shares of Atossa Therapeutics (NASDAQ:ATOS) in a report issued on Tuesday morning, Marketbeat Ratings reports. HC Wainwright currently has a $4.00 target price on the stock.

Several other equities analysts have also recently weighed in on ATOS. Cantor Fitzgerald reiterated an overweight rating on shares of Atossa Therapeutics in a research note on Friday, January 12th. StockNews.com cut shares of Atossa Therapeutics from a hold rating to a sell rating in a research note on Monday, March 18th.

Atossa Therapeutics Stock Down 3.5 %

Shares of NASDAQ ATOS opened at $1.37 on Tuesday. The firm’s 50-day moving average price is $1.39 and its 200-day moving average price is $0.99. The company has a market cap of $171.67 million, a PE ratio of -5.71 and a beta of 1.20. Atossa Therapeutics has a 52-week low of $0.59 and a 52-week high of $2.31.

Atossa Therapeutics (NASDAQ:ATOS) last issued its quarterly earnings data on Monday, April 1st. The company reported ($0.06) earnings per share for the quarter. As a group, equities research analysts anticipate that Atossa Therapeutics will post -0.28 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, Director Jonathan Finn bought 25,000 shares of the firm’s stock in a transaction on Wednesday, April 10th. The shares were bought at an average price of $1.77 per share, for a total transaction of $44,250.00. Following the purchase, the director now owns 25,000 shares in the company, valued at $44,250. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 7.80% of the stock is owned by company insiders.

Institutional Investors Weigh In On Atossa Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Connor Clark & Lunn Investment Management Ltd. bought a new stake in Atossa Therapeutics during the 3rd quarter worth approximately $98,000. XTX Topco Ltd bought a new stake in Atossa Therapeutics during the 2nd quarter worth approximately $50,000. Two Sigma Securities LLC bought a new stake in Atossa Therapeutics during the 2nd quarter worth approximately $32,000. Renaissance Technologies LLC raised its stake in Atossa Therapeutics by 14.7% during the 2nd quarter. Renaissance Technologies LLC now owns 1,074,070 shares of the company’s stock worth $1,353,000 after acquiring an additional 138,000 shares during the period. Finally, LPL Financial LLC bought a new stake in Atossa Therapeutics during the 2nd quarter worth approximately $59,000. Institutional investors own 12.74% of the company’s stock.

About Atossa Therapeutics

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing medicines in the areas of unmet medical need in oncology. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.